Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | NOX2: a potential immune checkpoint for inhibition in AML

Anna Martner • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Checkpoint inhibitors

Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group’s recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.

More from Anna Martner

1:50
Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
Anna Martner • 25 Feb 2019
1:50
What are the advantages of using histamine dihydrochloride together with immunotherapy?
Anna Martner • 24 Feb 2017
6:18
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Anna Martner • 24 Feb 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals